troglitazone has been researched along with Precancerous Conditions in 5 studies
Troglitazone: A chroman and thiazolidinedione derivative that acts as a PEROXISOME PROLIFERATOR-ACTIVATED RECEPTORS (PPAR) agonist. It was formerly used in the treatment of TYPE 2 DIABETES MELLITUS, but has been withdrawn due to hepatotoxicity.
Precancerous Conditions: Pathological conditions that tend eventually to become malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Treatment with troglitazone increased apoptosis and decreased polyamine content and ornithine decarboxylase (ODC) activity in the colonic mucosa of rats treated with AOM." | 1.31 | Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats. ( Hosokawa, M; Kohno, H; Okumura, A; Takashima, S; Tanaka, T; Yamaguchi, N; Yoshitani , S, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 5 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Jin, M | 1 |
| Saekusa, Y | 1 |
| Dewa, Y | 1 |
| Nishimura, J | 1 |
| Matsumoto, S | 1 |
| Shibutani, M | 1 |
| Hasumi, K | 1 |
| Mitsumori, K | 1 |
| Yoshida, K | 1 |
| Hirose, Y | 1 |
| Tanaka, T | 3 |
| Yamada, Y | 1 |
| Kuno, T | 1 |
| Kohno, H | 3 |
| Katayama, M | 1 |
| Qiao, Z | 1 |
| Sakata, K | 1 |
| Sugie, S | 1 |
| Shibata, T | 1 |
| Mori, H | 1 |
| Mehta, RG | 1 |
| Williamson, E | 1 |
| Patel, MK | 1 |
| Koeffler, HP | 1 |
| Yoshitani, S | 1 |
| Takashima, S | 2 |
| Okumura, A | 2 |
| Murakami, A | 1 |
| Hosokawa, M | 2 |
| Yoshitani , S | 1 |
| Yamaguchi, N | 1 |
5 other studies available for troglitazone and Precancerous Conditions
| Article | Year |
|---|---|
Hepatocarcinogenic susceptibility of rasH2 mice to troglitazone in a two-stage hepatocarcinogenesis model.
Topics: Animals; Biomarkers, Tumor; Body Weight; Carcinogens; Chromans; Disease Models, Animal; Disease Susc | 2009 |
Inhibitory effects of troglitazone, a peroxisome proliferator-activated receptor gamma ligand, in rat tongue carcinogenesis initiated with 4-nitroquinoline 1-oxide.
Topics: 4-Nitroquinoline-1-oxide; Animals; Antineoplastic Agents; Bromodeoxyuridine; Carcinogens; Chromans; | 2003 |
A ligand of peroxisome proliferator-activated receptor gamma, retinoids, and prevention of preneoplastic mammary lesions.
Topics: 9,10-Dimethyl-1,2-benzanthracene; Animals; Anticarcinogenic Agents; Antineoplastic Agents; Carcinoge | 2000 |
Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats.
Topics: Animals; Anticarcinogenic Agents; Azoxymethane; Bezafibrate; Cell Division; Chromans; Colitis; Colon | 2001 |
Troglitazone, a ligand for peroxisome proliferator-activated receptor gamma, inhibits chemically-induced aberrant crypt foci in rats.
Topics: Animals; Antineoplastic Agents; Apoptosis; Azoxymethane; Biogenic Polyamines; Carcinogens; Chromans; | 2001 |